CD33 (CD33 Molecule)

Together, these findings establish CLL-1-targeted nanobody-based CAR-T cells as a precision-engineered immunotherapy with potent anti-leukemic activity, reduced off-target toxicity, and enhanced translational potential. This platform provides a promising therapeutic avenue to overcome current barriers in AML CAR-T development and improve patient outcomes.

These results suggest that E-BVL may influence apoptotic and proliferative pathways in THP-1 leukemia cells. Overall, this study highlights B. vulgaris leaf extract as a promising natural source of bioactive compounds for anti-leukemic research, without specifically implicating berberine, which was not detected in the extract.

P1, N=21, Active, not recruiting, Senti Biosciences | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Feb 2026

P1, N=2, Completed, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Completed | N=102 --> 2

In the in vivo experiments, mice bearing Molm13-Luciferase tumor cells were assigned to different treatment groups and were administered with saline, Gemtuzumab-MMAE, or Clone3HM-MMAE...Clone3HM-MMAE, in particular, demonstrated excellent anti-tumor activity along with a strong safety profile. These results strongly support the further development of targeted therapeutic strategies for AML.

The t(16;21)(p11;q22) FUS::ERG fusion gene is rare in pediatric AML and associated with poor prognosis. Allo-HSCT may mitigate the adverse prognostic impact of the FUS::ERG fusion gene and contribute to prolonged survival.

ETP-ALL represents a biologically distinct T-ALL subtype with inferior early treatment responses. The TCCSG six-marker scoring system is reliable, accurate, and practical for routine diagnosis, particularly in resource-limited settings.

We demonstrate that DISCERN can track phenotypic plasticity in leukemia cells and identify stem-like subsets in leukemia xenograft models. This cost-effective and robust platform provides a promising tool for AML risk stratification, relapse prediction, and precision therapy.

This allogeneic CAR T product demonstrated acceptable safety and preliminary anti-leukemic activity. ClinicalTrials.gov: NCT05984199.

In AML, it correlated with CD33 expression and inv(16)/t(16;16). In conclusion, mesothelin is rare in ALL but enriched in specific AML subtypes and not prognostic for survival.

Validation of the prognostic FCM-PS in an independent patient cohort confirmed good discrimination performance (AUC: 0.70). We introduce a unique, easy-to-use prognostic FCM-PS score (panel: CD45/CD34/CD117/CD33/CD19/CD123/HLA-DR) for OS in MDS, allowing refined risk stratification for IPSS-R subgroups.

This indicates that the multistep molecular process of M-MDSC induction from PBMCs by the co-presence of HDBCLs begins with a transient early hyper-inflammatory phase and transitions into a post-inflammatory immunosuppressive phase. Our study demonstrates that treatments that target specific molecular phases regulated by cytokines could reduce M-MDSC induction and improve the effectiveness of immune cell therapy.